No Data
Zai Lab Limited (ZLAB): Top ADR Stock According to Hedge Funds
ZAI LAB: 2024 INTERIM REPORT
Express News | Zai Lab to Present Preliminary Data From Phase 1 Trial of Zl-1218, an Investigational Anti-Ccr8 Antibody for the Treatment of Advanced Solid Tumors, at Esmo Congress 2024
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
HK Stocks | Zai Lab (09688) rises more than 4%, total revenue in the first half of the year increases by more than 40%, and the growth of Egamod is strong.
Zai Lab (09688) rose more than 4%, as of the time of publication, up 4.08% to HK$14.8, with a turnover of 17.6165 million Hong Kong dollars.
Zai Lab (09688.HK) has achieved impressive performance in the first half of the year, with a significant increase of 42% in net product revenue.
On August 27, Gelunhui announced that zai lab (09688.HK) recorded a net increase of $55.6 million (or 42%) to $0.187 billion in product revenue for the six months ended June 30, 2024, mainly driven by the increase in sales since its launch in September 2023 and inclusion in the national medical insurance catalog in January 2024. The net growth in product revenue for the six months ended June 30, 2024 was also boosted by the increase in sales volume of Zule, Niuzaiyue, and Qingyue. Zule's sales remain strong as it continued to be listed in the national medical insurance catalog for the first quarter of 2024.
No Data
